Current Investors

Argos Therapeutics is funded by a broad syndicate of value-added life science investors:

ABN AMRO Capital
ABN AMRO Capital is a wholly owned private equity subsidiary of ABN AMRO Bank N.V. of the Netherlands. It currently has an investment portfolio amounting to €2 billion. Of this, some €80 million is currently invested in 27 private companies active in drug discovery and development as well as new medical devices, in both Europe and the US.

The Aurora Funds
Founded in 1994, The Aurora Funds is a venture capital firm that provides capital, connections and strategic help to entrepreneurs with early stage life science and information technology companies, primarily in the Southeastern and Mid-Atlantic United States. Aurora typically invests in seed and first round financing opportunities. The firm has more than $155 million of total capital under management and is currently investing out of its fourth fund of $85 million. The firm has the capacity to invest between $4 million and $7 million throughout the life cycle of an investment.

CDP Capital Technology Ventures
CDP Capital Technology Ventures is an investment arm of the Caisse de Depots et Placements de Quebec.

GeneChem Therapeutics Venture Fund L.P. is fully dedicated to making investments in companies concentrating their research and development efforts to the field of proliferative disorders, e.g. cancer and infectious diseases. This is the second GeneChem fund and it was launched in 2000 with a committed capital of $137 million. It has invested in over 15 companies.

Intersouth Partners
Intersouth is one of the nation’s most experienced early stage venture capital firms, managing more than $500 million in six venture capital partnerships since 1985. As one of the largest early stage firms in the Southeast and Mid-Atlantic regions, it has invested in more than 75 companies, and focuses on the life sciences and information technology sectors.

MDS Capital
MDS Capital Corp. and affiliates, with more than $1 billion under management, is a leading North American venture capital company focused exclusively on providing financial support and other services to help build emerging life science companies.

TFG Capital AG
Once a pioneer of Germany’s venture capital culture (established 1994) and one of the country’s leading venture capital companies, the company today presents a forward-looking profile adapted to changes in the market and focuses the so-called Investment Engineering. Investment Engineering stands for an innovative approach in the private equity industry, connecting independent advice and supply of capital for companies that, despite being fundamentally sound, have experienced difficulty as a result of management problems, financial bottlenecks or collapsing markets.

TFG Capital sees itself as a problem solver and a partner, primarily for listed investments. The common goal is to handle all the challenges that arise to secure the future, with the aim of creating value-added for all parties involved. The guarantee of success is our many years of investment experience and the clear analysis expertise of the TFG team, our established proximity to the capital market and a highly qualified network of partners that supports TFG Capital in its investments.

Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth.

TVM funds have made investments in over 220 technology companies in Europe and the United States. Many of these enterprises went public on U.S. or European stock exchanges or were sold to strategic acquirers.

A major objective of our investment strategy is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic, thereby increasing their opportunity to develop into dominant players in their markets.